HC Wainwright Has Bullish Estimate for CRVS FY2025 Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Equities researchers at HC Wainwright boosted their FY2025 earnings per share estimates for Corvus Pharmaceuticals in a report released on Wednesday, March 26th. HC Wainwright analyst S. Lee now anticipates that the company will earn ($0.43) per share for the year, up from their prior forecast of ($0.44). HC Wainwright has a "Buy" rating and a $11.00 price objective on the stock. The consensus estimate for Corvus Pharmaceuticals' current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals' FY2027 earnings at ($0.32) EPS.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last announced its earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.06).

Separately, Oppenheimer reaffirmed an "outperform" rating and set a $15.00 price objective (up previously from $14.00) on shares of Corvus Pharmaceuticals in a research report on Wednesday, March 26th. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Corvus Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $15.67.

Remove Ads

Corvus Pharmaceuticals Price Performance

Shares of Corvus Pharmaceuticals stock traded down $0.02 during midday trading on Friday, hitting $3.16. The company had a trading volume of 448,559 shares, compared to its average volume of 581,803. Corvus Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $10.00. The business's 50 day simple moving average is $4.57 and its two-hundred day simple moving average is $6.06. The stock has a market cap of $203.05 million, a PE ratio of -3.41 and a beta of 0.91.

Institutional Investors Weigh In On Corvus Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Corvus Pharmaceuticals by 64.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company's stock valued at $724,000 after buying an additional 53,809 shares in the last quarter. State Street Corp lifted its holdings in shares of Corvus Pharmaceuticals by 48.2% during the third quarter. State Street Corp now owns 178,246 shares of the company's stock valued at $941,000 after acquiring an additional 57,943 shares during the period. Jane Street Group LLC acquired a new stake in shares of Corvus Pharmaceuticals in the 3rd quarter valued at $265,000. XTX Topco Ltd acquired a new stake in shares of Corvus Pharmaceuticals during the 3rd quarter worth about $74,000. Finally, Geode Capital Management LLC lifted its holdings in Corvus Pharmaceuticals by 22.4% during the 3rd quarter. Geode Capital Management LLC now owns 563,009 shares of the company's stock valued at $2,974,000 after purchasing an additional 102,869 shares during the last quarter. 46.64% of the stock is owned by institutional investors and hedge funds.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.